Free Newsletter

Related Topics >> FDA | pharmaceuticals | Alzheimer's

SPOTLIGHT: FDA allows Memory to restart trial

December 10, 2006 — 8:01pm ET

Free newsletter via e-mail

FDA's Pazdur offers advice to cancer drug developers
FDA picking up the pace on '08 approvals
Press Release: Memory Pharmaceuticals Announces Release of Clinical Hold on MEM 3454
ALSO NOTED: Rosetta cuts share price; FDA committee to focus on Pentacel; and much more...
Wyeth stumbles badly trying to develop new drugs

Tools

Subscribe
Email
Print
Comment
Contact Author
Reprint

After being hampered by regulatory concerns regarding potential drug impurities and changes to toxicology reports, Memory Pharma says that the FDA has given it a green light to resume a mid-stage clinical trial of MEM 3454 for Alzheimer's in the first quarter of the new year. Release

SHARE
WITH: